AcelRx Pharmaceuticals to acquire Tetraphase Pharmaceuticals

This article was originally published here

The CVR represents additional consideration upon XERAVA™ (eravacycline for injection) achieving certain net sales starting in 2021.  The acquisition is consistent with AcelRx’s strategic plan to expand and

The post AcelRx Pharmaceuticals to acquire Tetraphase Pharmaceuticals appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply